BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Conference Call February 26, 2024 8:30 AM ET

Company Participants

John Bluth - Chief Communications Officer

Jon Stonehouse - Chief Executive Officer

Ryan Arnold - Chief Medical Officer

Charlie Gayer - Chief Commercial Officer

Anthony Doyle - Chief Financial Officer

Conference Call Participants

Tazeen Ahmad - Bank of America

Brian Abrahams - RBC Capital Markets

Jessica Fye - JP Morgan

Liisa Bayko - Evercore ISI

Stacy Ku - TD Cowen

Serge Belanger - Needham & Co

Gena Wang - Barclays

Francois Brisebois - Oppenheimer

Maury Raycroft - Jefferies

Operator

Good day, and welcome to the BioCryst Fourth Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

John Bluth

Thank you very much. Good morning and welcome to BioCryst fourth quarter and year-end, 2023 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website.

Participating with me today are CEO Jon Stonehouse; CFO Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief Medical Officer Dr. Ryan Arnold. Following our remarks, we'll answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements.

For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today's conference call includes non-GAAP pro forma financial measures. For a reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the press releases section of our Investor Relations website at biochrist.com.

Now, I'd like to turn the call over to Jon Stonehouse.

Jon Stonehouse

Thanks, John. 2023 was another impressive year for ORLADEYO starting with generating $326 million in revenue in just the third year of launch. We continue to make great progress toward our goal of a global peak revenue of $1 billion.